plasma cell dyscrasia may play a part in triggering the disease. In amyloidosis there is a clear relationship between monoclonal gammopathy and AL deposits. In POEMS syndrome, the plasma cell dyscrasia has a pathogenetic role, but no clear relationship has been found between the gammopathy and the clinical manifestations, which rather appear to be due to high VEGF levels. However, both these entities improve when the plasma cell dyscrasia and the monoclonal component are eradicated.5,6

The risk of death from autologous stem cell transplantation, evaluated at 3% to 5% in multiple myeloma,7 seems to be counterbalanced by its efficacy and by the poor prognosis of gammopathy-associated SLONM. Nevertheless, in AL amyloidosis, melphalan plus high dose dexamethasone was as effective and much safer than melphalan plus bone marrow transplantation.6 These two attitudes will have to be further evaluated in SLONM.


*Senior authors.

From the Service de Médecine Interne 1 (O.B., S.H.), Institut de Myologie (P.L., M.F., B.E.), Laboratoire de Neuropathologie (O.D.), Laboratoire UMR S 787-UMR Groupe Myologie (S.S.), Laboratoire d'Immunochimie (L.M.), and Service d'Hématologie (S.C., N.A., V.L.), Hôpital Pitie-Salpêtrière, Faculté de Médecine Pierre et Marie Curie, Assistance Publique Hôpitaux de Paris, France.

Disclosure: The authors report no disclosures.

Received November 14, 2007. Accepted in final form January 3, 2008.

Address correspondence and reprint requests to Dr. Olivier Benveniste, Service de Médecine Interne 1, Groupe Hospitalier Pitie-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75651 Paris Cedex 13, France; olivier.benveniste@psl.aphp.fr

Copyright © 2008 by AAN Enterprises, Inc.

ACKNOWLEDGMENT

The authors thank Gildas Debaussart from Association Française contre les Myopathies for technical assistance.


SPORADIC LATE-ONSET NEMALINE MYOPATHY EFFECTIVELY TREATED BY MELPHALAN AND STEM CELL TRANSPLANT

Sporadic late-onset nemaline myopathy (SLONM) is a rare, late-onset myopathy that progresses subacutely. Limb-girdle weakness and atrophy predominate the clinical picture.1 SLONM is sporadically associated with a monoclonal gammopathy, which portends an unfavorable outcome.1,6 We report the successful treatment of a patient with SLONM and monoclonal gammopathy with melphalan and autologous stem cell transplantation.

Clinical case. In October 2004, a 38-year-old man with no family history of myopathy started feeling fa-

See page 531

Table

<table>
<thead>
<tr>
<th>Outcome of muscle functions</th>
<th>Month 0</th>
<th>Month 0</th>
<th>Month 3</th>
<th>Month 6</th>
<th>Month 12</th>
<th>Month 18</th>
<th>Month 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myalgia</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Arm abduction</td>
<td>45°</td>
<td>30°</td>
<td>45°</td>
<td>60°</td>
<td>ND</td>
<td>120°</td>
<td>160°</td>
</tr>
<tr>
<td>Head drop</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Legs held outstretched at 45 deg supine</td>
<td>22 s</td>
<td>Impossible</td>
<td>60 s</td>
<td>&gt;75 s</td>
<td>&gt;75 s</td>
<td>&gt;75 s</td>
<td>&gt;75 s</td>
</tr>
<tr>
<td>Gait/time necessary to walk 10 meters alone</td>
<td>With help of someone/ND</td>
<td>Impossible/ND</td>
<td>With help of someone/ND</td>
<td>With 2 canes/18 s</td>
<td>With one cane/ND</td>
<td>With one cane/13 s</td>
<td>Alone/11 s</td>
</tr>
<tr>
<td>Standing up alone from a chair (no. of times in 1 min)</td>
<td>Impossible</td>
<td>Impossible</td>
<td>1</td>
<td>3</td>
<td>7</td>
<td>10</td>
<td>12</td>
</tr>
</tbody>
</table>

Month 0 – date of autologous peripheral stem cell transplantation.
tigated. In April 2005, he noted weakness of neck extensors, followed by weakness and atrophy of his arms and shoulders. Impairment of speech and swallowing gradually developed. In January 2006, he had mild exertional dyspnea. Laboratory investigations revealed normal CK, absence of anti-AChR antibodies, and negative viral serology, including HIV. MRI of the cervical spine was normal. Electromyography showed small, polyphasic units, with moderate spontaneous activity. Right quadriceps muscle biopsy showed atrophic fibers, but no signs of inflammation. An M-protein IgG kappa spike of 7.4 g/L was identified on serum electrophoresis and was confirmed by immunofixation. Conventional X-ray of the skeleton revealed no lytic lesions. Results of bone marrow biopsy showed an increase of monoclonal plasma cells (10–20%, almost exclusively light chain kappa positive cells), without signs of amyloidosis. Hence, monoclonal gammopathy of undetermined significance was diagnosed. The neuromuscular differential diagnosis included motor neuron disorder and inflammatory myopathy. The patient was treated with prednisone 70 mg/day for 1 month; however, dysarthria, dysphagia, and muscle weakness increased (shoulder abduction MRC2; neck extension MRC3; elbow flexion and extension MRC4) (figure).

Revision of the muscle biopsy showed not only small groups of angulated or flattened atrophic fibers, but also scattered fibers with internal nuclei, basophilic areas, or irregular ATP-ase staining and several lobulated fibers. On trichrome staining many atrophic fibers were completely filled with nemaline rods, but also larger fibers showed central or subsarcolemmal accumulations of rods, sometimes accompanied by small vacuoles. Both immunohistochemical staining with α-actinin antibodies (figure) and electron microscopy confirmed the abundance of these rods, classically composed of Z-band material. No amyloid was detected. Staining with kappa, lambda, and IgG antibodies revealed no abnormalities. Mutation analysis of the NEB, TMP3, and ACTA1 genes was normal. SLONM associated with monoclonal gammopathy was diagnosed.

Treatment with prednisone had reduced the presence of the M-protein in serum. To further eradicate the plasma cell clone in the bone marrow, experimental treatment with one cycle of melphalan (70 mg/m²) with peripheral stem cell collection was performed in March 2006. In May 2006 a course of high dose melphalan with autologous stem cell transplantation was performed. Two months later no M-protein was detectable in the serum, and on bone marrow examination no monoclonal plasma cells were detected. The patient attended a rehabilitation program. 15-Month clinical follow-up showed apparent improvement of muscle force and mass (shoulder abduction MRC3; neck extension MRC4; elbow flexion MRC4; elbow extension MRC5). Functional improvement was also impressive: he was able to walk upstairs and run again, speaking and swallowing were normal, and he had started working again. Cardiac and pulmonary screening were then

Copyright © by AAN Enterprises, Inc. Unauthorized reproduction of this article is prohibited.
normal. Right quadriceps muscle biopsies in August 2006 and August 2007 showed scattered atrophic, lobulated fibers. Nemaline rods were observed neither in the Gomori trichrome staining nor on electron microscopy.

Discussion. SLONM is an atypical disorder that normally presents after age 40 and progresses sub-acutely. Limb-girdle weakness and atrophy predominate the clinical picture, but distal weakness, head drop, respiratory insufficiency, and dysphagia can also occur.1 Although fasciculations and hyperreflexia are absent, patients may be misdiagnosed with motor neuron disease. Recognition of nemaline rods on trichrome staining is crucial. This can be confirmed by immunohistochemical staining with alpha-actinin antibodies of the muscle biopsy.

Presence of monoclonal gammopathy in SLONM portends an unfavorable outcome: the majority of these patients die within 1 to 5 years of respiratory failure, despite immunosuppressive treatment.3 Presence of a monoclonal protein at the sarcolemma and responsiveness to immunosuppressive treatment are suggestive of an autoimmune origin.1,4,5 In contrast to these previously reported cases, this patient showed significant improvement of muscle strength and function that was accompanied by a remarkable improvement of the muscle histology in response to treatment. Treatment with high dose melphalan and stem cell transplantation has a relatively low mortality when cardiac or visceral involvement is absent.7 Since the natural course of SLONM with monoclonal gammopathy is devastating, this report is imperative and calls for further study. Finally, it stresses the importance of recognition of this remarkable mimic of motor neuron disease.


www.neurology.org Offers Important Information to Patients and Their Families

The Neurology® Patient Page provides:
• A critical review of ground-breaking discoveries in neurologic research that are written especially for patients and their families
• Up-to-date patient information about many neurologic diseases
• Links to additional information resources for neurologic patients

All Neurology Patient Page articles can be easily downloaded and printed, and may be reproduced to distribute for educational purposes. Click on the Patient Page icon on the home page (www.neurology.org) for a complete index of Patient Pages.